Take Me Heme, Binding Modes: Wrapping up the CYP Inhibition Challenge
Let’s have those country roads take us to the finish line! After 2 months and more than 6,000 submissions, we finally have our winners.
Let’s have those country roads take us to the finish line! After 2 months and more than 6,000 submissions, we finally have our winners.
Co-folding has taken over protein-ligand structure prediction, but can it find the right pose? Key learnings from PXR structure prediction in our recent blind challenge.
The Heme-coming last dance begins: Interim leaderboard release & announcing a new Structure Track
Announcing the open-source release of our production-ready blind challenge infrastructure template, enabling anyone to spin up a molecular prediction competition in an afternoon.
Exploring the limits of ligand-based ML models in predicting PXR induction, based on key learnings from our recent blind challenge.
Announcing the results of the PXR Blind Challenge — and the public release of the largest high-quality PXR induction dataset ever made available, with over 11,000 compounds.
We're halfway through the PXR Blind Challenge: unblinding the first data, freezing the leaderboard, and stepping into Phase 2 — plus a look at the response so far and what's next.
Benchmarks are everywhere in ML — but when is a leaderboard gap real? Jon Swain on the statistics of comparing blind challenge entries and separating genuine performance from noise.
Launch details for the PXR induction challenge, including the dataset, rules, and practical guidance for participants.
Lessons and reflections from the OpenADMET-ExpansionRx blind challenge — evaluating whether zero-shot ADMET predictions can be trusted in real drug discovery settings.
An introduction to the next blind challenge and why blinded datasets remain important for realistic benchmarking.
Authors: Maria Castellanos, Hugo MacDermott-Opeskin, Jon Ainsley, Pat Walters DOI: 10.5281/zenodo.21784567 The ExpansionRx challenge, launched on October 27, 2025, closed two